What are the treatment options for excessive daytime sleepiness?

Treatment of Excessive Daytime Sleepiness

The treatment approach depends critically on the underlying etiology: for narcolepsy, use modafinil, pitolisant, sodium oxybate, or solriamfetol as first-line agents; for idiopathic hypersomnia, modafinil is the only strong recommendation; and for OSA-related residual sleepiness despite adequate primary therapy, solriamfetol, pitolisant, or modafinil are recommended. 1

Narcolepsy in Adults

Four medications carry STRONG recommendations from the American Academy of Sleep Medicine (AASM) for narcolepsy treatment, meaning clinicians should use them under most circumstances:

• Modafinil is a first-line option with strong evidence 1
• Pitolisant (histamine H3 receptor inverse agonist) has strong recommendation status 1
• Sodium oxybate carries a strong recommendation but requires careful monitoring due to its Schedule III status and black-box warning for respiratory/CNS depression, particularly when combined with alcohol or sedatives 1
• Solriamfetol (dual dopamine-norepinephrine reuptake inhibitor) has strong evidence and demonstrated robust efficacy in randomized controlled trials 1, 2

Conditional (second-line) options when first-line agents fail or are not tolerated:

• Armodafinil may be considered 1
• Dextroamphetamine is an option but requires caution regarding substance abuse history 1
• Methylphenidate (Schedule II) can be used but demands careful monitoring and documentation due to controlled-substance regulations 1

Idiopathic Hypersomnia in Adults

Modafinil is the only medication with a STRONG recommendation for idiopathic hypersomnia and should be prescribed as first-line therapy. 1, 3

Low-sodium oxybate received FDA approval in 2021 as the first medication specifically indicated for idiopathic hypersomnia, demonstrating efficacy in reducing daytime sleepiness, decreasing sleep inertia, and improving daily functioning in randomized controlled trials. 3

When modafinil is ineffective or not tolerated, conditional recommendations include:

• Clarithromycin (off-label use as wake-promoting agent) 1, 3
• Methylphenidate (Schedule II; requires monitoring for substance abuse risk and carries fetal-harm warnings) 1, 3
• Pitolisant (note: reduces oral contraceptive effectiveness, requiring alternative birth control counseling) 1, 3
• Sodium oxybate (Schedule III; black-box warning for respiratory/CNS depression and abuse risk) 1, 3

OSA-Related Excessive Daytime Sleepiness

CPAP is the first-line therapy for OSA patients to improve excessive daytime sleepiness and must be optimized before considering wake-promoting agents. 4

For residual EDS despite adequate and adherent CPAP therapy (after excluding other causes of sleepiness):

• Solriamfetol, pitolisant, or modafinil are recommended with strong evidence (Grade 1A) 4
• Solriamfetol demonstrated the lowest risk of all-cause discontinuation in network meta-analysis and ranked highest for efficacy on the Epworth Sleepiness Scale 5
• Pitolisant exhibited minimal risks of adverse events leading to treatment discontinuation and treatment-emergent adverse events 5
• Recent phase 3 trial in China confirmed solriamfetol's substantial efficacy and acceptable safety profile in OSA patients with EDS 6

For patients who refuse, are intolerant of, or non-adherent to CPAP:

• Solriamfetol or pitolisant are recommended (Grade 1A) 4
• Modafinil may be considered (Grade 2B) 4
• Regular encouragement to continue conventional OSA therapy should be provided throughout pharmacologic treatment 4

Secondary Hypersomnias

For hypersomnia secondary to Parkinson's disease or dementia with Lewy bodies:

• Modafinil or armodafinil are suggested (conditional recommendations) 1
• Sodium oxybate may be considered for Parkinson's-related hypersomnia 1

For post-traumatic hypersomnia (traumatic brain injury):

• Armodafinil or modafinil are suggested (conditional recommendations) 1

For hypersomnia secondary to myotonic dystrophy:

• Modafinil is suggested (conditional recommendation) 1

For Kleine-Levin syndrome:

• Lithium is suggested (conditional recommendation) 1

Critical Safety Considerations

All pharmacologic options (modafinil, clarithromycin, methylphenidate, pitolisant, sodium oxybate, and low-sodium oxybate) carry warnings of potential fetal harm based on animal studies; pregnancy risk assessment is mandatory before prescribing. 3

Controlled substances require heightened vigilance:

• Methylphenidate (Schedule II) and both forms of oxybate (Schedule III) demand careful monitoring, documentation, and adherence to controlled-substance regulations 3
• Sodium oxybate has black-box warnings for respiratory and CNS depression, particularly when combined with alcohol or sedatives 3

Drug interactions to monitor:

• Pitolisant diminishes oral contraceptive effectiveness, necessitating counseling on alternative birth control methods 3
• Solriamfetol is renally excreted with no known drug interactions, offering an advantage in polypharmacy situations 2

Condition-specific adverse event profiles for modafinil vary:

• Narcolepsy patients have elevated risks of diarrhea (RR: 2.16) and nausea (RR: 2.44) 7
• OSA patients have higher risks of insomnia (RR: 5.82), anxiety/nervousness (RR: 3.26), and headache (RR: 1.92) 7

Regular monitoring of efficacy and safety is required using subjective EDS scales (ESS with MCID of 2-3 points), supplemented by objective assessments when available, with strict surveillance for adverse effects including drug dependence, addiction, and cardiovascular events. 4

Assessment Tools

The Epworth Sleepiness Scale (ESS) is the recommended subjective tool for diagnosis, severity assessment, and monitoring treatment effects, with a clinical threshold of 10 points and minimum clinically important difference of 2-3 points. 4

The Maintenance of Wakefulness Test (MWT) and Multiple Sleep Latency Test (MSLT) are objective tools for ruling out comorbid sleep disorders but should not be used independently for diagnosis. 4